Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,574.84
(
-0.75%
)
US TECH 100
23,589.60
(
-0.87%
)
Dow Jones
45,826.44
(
-0.86%
)
Brent Oil
105.88
(
-0.66%
)
Bitcoin
69,662.43
(
-2.22%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 108329

Sunday, 11/07/2010 1:31:13 PM

Sunday, November 07, 2010 1:31:13 PM

Post# of 257259

While the results of the EMINENCE trial was successful, I'm not sure whether the degree of success would position M118 with Lovenox or the new drugs coming on line.

Actually, the main competition for M118 is Angiomax.

Lovenox is not a major player in ACS, and the new oral anticoagulants have not yet produced compelling ACS data (e.g. #msg-39151366). Moreover, the new oral anticoagulants are not reversible, which is a significant drawback in acute-care settings.

Please see #msg-39146357 for background info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today